2.32
-0.11(-4.53%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.45 |
| Day High | 2.45 |
| Day Low | 2.29 |
| 52-Week High | 3.54 |
| 52-Week Low | 1.02 |
| Volume | 1.73M |
| Average Volume | 1.45M |
| Market Cap | 230.1M |
| PE | -1.63 |
| EPS | -1.42 |
| Moving Average 50 Days | 2.05 |
| Moving Average 200 Days | 1.95 |
| Change | -0.11 |
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
GlobeNewswire Inc.
Dec 01, 2025 9:05 PM GMT
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
GlobeNewswire Inc.
Nov 03, 2025 12:00 PM GMT
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vis